Keyword: drug plan management

527 results found
Virtual care among ‘dramatic change’ predicted for benefits plans in future

One of the biggest changes in the benefits industry over the next five years will be the movement towards virtual care as a standalone category, said Tim Clarke at Benefits Canada‘s Benefits & Pension Summit in Toronto on Monday. “Whether you’re talking about telemedicine, whether you’re talking about virtual [cognitive behavioural therapy], you think about […]

  • By: Ryan Murphy
  • April 16, 2018 September 13, 2019
  • 15:00
A look at one company’s experience with pharmacogenetic testing

At General Electric Co. Canada, part of Dr. Sol Sax’s job as consultant and medical director is to support and refine the company’s disability management process. That process includes everything from how the company helps to prevent workers from going on disability to monitoring them while they’re away and supporting their return to work. As part of its […]

Lower generic prices not a cure for drug cost pressures

The announcement in late January that 70 of the most commonly prescribed drugs will see their prices fall by as much as 40 per cent on April 1 was certainly welcome news for plan sponsors. The deal, reached by the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association, will bring the cost of some generic products down […]

  • March 26, 2018 September 13, 2019
  • 16:14
How changing public coverage could affect the pharmaceuticals industry

The hepatitis C hump is over. Since 2014, Health Canada has approved several promising medications for the disease. While the direct-acting antivirals offer cure rates of more than 90 per cent, they cost tens of thousands of dollars, and benefits plans felt the pinch. But now, “after an initial spike in treatment requests, claims have […]

Green Shield Canada rolls out biosimilar transition program

Green Shield Canada is rolling out a new biosimilar transition program as a pilot project through the first half of 2018, with an aim to extending it to all of its employer clients by the end of the year. The program, which was designed to help plan members transition from an originator drug to a corresponding biosimilar, will initially focus […]

  • By: Staff
  • March 7, 2018 September 13, 2019
  • 15:45
Rising drug costs a source of pain? There’s a tiered formulary for that

Anyone who’s ever suffered from chronic pain will tell you it’s a great motivator. When you’re in pain, you’ll go to great lengths and will try just about anything to eliminate or reduce it. I know that from experience. The rising cost of prescription drugs is becoming a persistent source of pain for many employers. For some, […]

  • February 21, 2018 September 13, 2019
  • 14:01
Patient advocacy organizations urge government to halt drug-pricing review

A group of 28 patient advocacy organizations are urging Health Canada to stop its review of drug pricing. The federal government announced changes to drug price regulation in December 2017, setting out proposals through the Patented Medicine Prices Review Board that it estimates will deliver $12.6 billion in net benefits over 10 years through lower drug costs. Read: Feds […]

  • By: Staff
  • February 15, 2018 September 13, 2019
  • 16:50
Almost a million Canadians cut food, heat spending to pay for drugs

Almost one million Canadians cut spending on necessities such as food and heating to afford prescription drugs in 2016, according to a report by researchers at the University of British Columbia, Simon Fraser University, McMaster University and the University of Toronto. The report, which used data from Statistics Canada’s 2016 Canadian community health survey, also found 1.69 […]

  • By: Ryan Murphy
  • February 13, 2018 September 13, 2019
  • 09:00
B.C. to reduce prescription drug deductibles for low-income earners

British Columbia’s plan to eliminate or reduce prescription drug deductibles for low-income earners could also lead to lower drug costs for plan sponsors in the province. While Nick Gubbay, a principal and group benefits consultant at Eckler Ltd. in Vancouver, says the impact is likely to be most material for group plans providing benefits to […]

  • By: Ryan Murphy
  • February 12, 2018 September 13, 2019
  • 10:15
Editorial: Projections for drug costs a mixed bag for plan sponsors

As the new year gets underway, it’s a busy season for predictions about what’s ahead for 2018. When it comes to employer-sponsored drug plans, costs have been a rising concern in recent years. According to projections released by Aon Hewitt in December, costs for extended health-care plans will likely rise by six per cent in […]